Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-021-06280-x.pdf
Reference99 articles.
1. Slamon DJCG, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 235:177–182
2. Katzorke NRB, Haeberle L et al (2013) Prognostic value of HER2 on breast cancer survival. J Clin Onc 31(15):600–640
3. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752
4. Slamon DJL-JB, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Eng J Med 344(344):783–792
5. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504–2512
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications;Current Heart Failure Reports;2024-09-10
2. Noncoding RNA-associated competing endogenous RNA networks in trastuzumab-induced cardiotoxicity;Non-coding RNA Research;2024-09
3. Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?;JCO Oncology Practice;2024-08
4. Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study;Reviews in Cardiovascular Medicine;2024-07-09
5. Risk prediction of heart diseases in patients with breast cancer: A deep learning approach with longitudinal electronic health records data;iScience;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3